Launch of the Mylan patch follows receipt of final approval from the US FDA for its abbreviated new drug application for the product.
Rivastigmine transdermal system, in dosings of 4.6 mg/24 hrs, 9.5 mg/24 hrs, and 13.3 mg/24 hrs, is indicated for the treatment of dementia associated with mild, moderate, and severe Alzheimer's disease and the treatment of mild to moderate dementia associated with Parkinson's disease.
Mylan president Rajiv Malik said, "The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug-delivery systems."
Mylan offers a broad and diverse portfolio, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products.
The company also has healthcare services to help patients access products and adhere to medication regimens to help promote better health outcomes. The company markets products in more than 165 countries and territories.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling